Welcome to the April issue of Drug Discovery News. Just eight short months after the termination announcement of Modern Drug Discovery, former MDD executives and editors present you with a unique and exclusive format for industry news.
Pall Corp. in late 2004 finalized the $32-million purchase of Ciphergen Biosystems Inc.’s process chromatography sorbent business. The acquisition of the BioSepra Process Division fills a crucial “missing link” in Pall’s extensive fluid management offerin
Predicant becomes the first company to gain technology rights as Caliper adopts a more expansive out-licensing strategy for its intellectual property estate
A powerful tool in modern oncology, immunotherapy doesn’t work the same for everyone. Researchers are exploring why and developing ways to improve its effectiveness.